At the request of Lipigon Pharmaceuticals AB, Lipigon Pharmaceuticals AB equity
rights will be traded on First North as from May 22, 2023.
Security name: LPGO TO3 240607
-------------------------------
Short name: LPGO TO3
-------------------------------
ISIN code: SE0019914XXX
-------------------------------
Orderbook ID: 293529
-------------------------------
Terms: One (1) equity right gives the right to subscribe for one (1) new share
in Lipigon Pharmaceuticals AB.
The exercise price when exercising the warrant shall amount to either
(i) 70 percent of the volume-weighted average price of the Company's
traded shares, during the period from and including May 6, 2024 to and
including May 20, 2024, however, not lower than the quotient value per
share and not higher than SEK 0.80 per share, or (ii) if the Company
publish a press release, in which the Company informs about the last
patient visit within the framework of the phase II study for the
Company's drug candidate Lipisense, 70 percent of the volume-weighted
average price of the Company's traded shares during a period of 10
trading days from and including the first trading day after the
publication of the aforementioned press release, however, not lower
than the quotient value per share and not higher than SEK 0.80 per
share.
--------------------------------------------------------------------------------
Subscr The earlier of (i) May 23, 2024 - June 7, 2024, or (ii) if the Company
iption publish a press relase in which the Company informs about the last
perio patient visit within the framework of the phase II study for the
d: Company's drug candidate Lipisense, the subscription period will last
10 trading days starting from and including the third trading day
following the last trading day taken into account when determining the
exercise price as described in "Terms" above.
--------------------------------------------------------------------------------
Last The earlier of (i) June 4, 2024 or (ii) if the Company publish a press
tradi relase in which the Company informs about the last patient visit within
ng the framework of the phase II study for the Company's drug candidate
day: Lipisense, 2 trading days prior to the last day of subscription in the
subscription period as desribed in "Subscription period" above.
--------------------------------------------------------------------------------
This information is distributed at the request of the Certified Adviser, G&W
Fondkommission. For further information, please call G&W Fondkommission on +46
8 503 000 50.© 2023 GlobeNewswire
